Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Sutro Biopharma reported its Q1 2026 financial results highlighting progress in its antibody drug conjugate (ADC) pipeline, including ongoing Phase 1 dose-escalation trial of STRO-004 with data expected mid-2026. The company is advancing IND submissions for next-generation ADCs STRO-006 and STRO-227, and dosing has begun for the first dual-payload …